Large granular lymphocyte (LGL) leukemia commonly occurs in the Fischer-344/N rat. The high spontaneous incidence complicates the interpretation of results from chronic carcinogenicity studies that use this rat strain. As a result, a comprehensive characterization of LGL leukemia is necessary to help understand the leukemogenic process and the applicability of staging for assessing the progression of this disease. In the current study, the proliferation rate of LGL leukemia cells from untreated control Fischer-344 (F-344) rats in 3 stages of leukemia compared to nonleukemic age-matched rats was determined by immunohistochemical staining for proliferating cell nuclear antigen (PCNA). In histologic sections of spleen from aged F-344/N rats affected by LGL leukemia, there was a significant increase of both PCNA labeling and mitotic indices that was most advanced in the spleen of rats with more severe LGL leukemia. These results support biological significance for the morphologic staging system currently in use.
INTRODUCTION
Large granular lymphocyte (LGL) leukemia is one of the more common spontaneous neoplastic diseases in aged Fischer-344/N rats (6, 9) . This disease affects 25% of the female and almost 50% of the male untreated Fischer-344/N rats on chronic toxicity/carcinogenicity studies (9) . Although the clinical and pathologic features of the disease and the morphological, functional, and immunophenotypic aspects of the neoplastic cells have been well characterized (12, 17-22, 25, 26) , the in viao proliferation rate of neoplastic LGLs is unknown.
LGLs originate in the bone marrow and mature without thymic influence (23) . The majority of LGLs are natural killer (NK) cells, which were originally thought to be nonproliferating. However, rapid re-newal of NK cells in the mouse spleen has been demonstrated (10, 13) . In recent reports, Vaage et al (23, 24) showed by in vitro pulse labeling of normal LGLs from 3 strains of rats (AO, PVG nude, and Fischer-344/N rats) with (3H]thymidine that 1-7% of cells in blood, spleen, and liver of euthymic and athymic rats were in S phase. Repetitive injections of [3H]thymidine between 2 and 7 days showed that about half of the blood and spleen LGLs formed by division of precursors.
Proliferating cell nuclear antigen (PCNA) is a DNA polymerase delta accessory protein and has been used to identify cells in the cell replication cycle. PCNA increases during the G, phase of the cell cycle. reaches its maximum in the S phase, and then declines during the G.-M phase. Differing immunostaining patterns of PCN A expression are present in the various phases of the cell proliferation cycle and therefore can be used to subdivide the phases of the cell cycle (3, 11) . PCNA is undetectable in most cells in the G,/G, stage (3) (4) (5) .
In the present study, immunocytochemical stain-ing for PCNA was used to determine a labeling index (LI) of cells in normal and the 3 stages of LGL leukemic spleens of aged Fischer-344 (F-344) rats to aid in the determination of the proliferation status of this neoplastic disease. The results of these studies show a significant increasing trend for PCNA labeling between more advanced stages of LGL leukemia. These findings support a biological relevance of the current morphologic staging scheme used by pathologists.
MATERIALS AND METHODS Tissue Specimens. Paraffin blocks containing spleens from 21 untreated F-344/N rats (18 males, 3 females), 26 mo old in a 2-yr chronic bioassay study, were obtained from the National Toxicology Program archives. Seventeen spleens were affected with LGL leukemia (6 were in Stage 1, 4 in Stage 2, and 7 in Stage 3), and 4 spleens were nonleukemic (Stage 0). The 3 female spleens were divided between Stage 2 ( 1 ) and Stage 3 (2) . An intestinal section from one of the nonleukemic rats was used as a positive control tissue. Six-Am sections were cut from each block and affixed to polY-L-lysine-coated glass slides (Histology Control Systems, Inc., Glen Head, NY).
Immunohistochemistry. Spleen sections were immunostained for the presence of PCNA by the streptavidin immunoperoxidase method modified and reported by Greenwell et al (7, 8) . Mounted sections were deparaffinized and rehydrated. Tissue sections were quenched for endogenous peroxidase in 3% H,O, for 10 min and rinsed. To enhance the immunostaining, spleen sections were heated in the microwave oven for 5-10 min, cooled, and then placed in a humidified chamber. The heating in a microwave oven has been suggested to alter the crosslinkages of proteins caused by the formalin fixation, which improves the exposure of the antigenic sites specific for the anti-PCNA antibody (15) . Normal goat serum (Vector Laboratories, Burlingame, CA) was used as a blocking reagent. The primary antibody, PCNA 19A2 (Coulter Immunology, Hialeah, FL), a murine monoclonal antibody against PCNA, was applied with 1 % bovine serum albumin for 30 min at room temperature. Subsequently, the slides were washed, incubated with a biotinylated antimouse IgM, v-chain-specific antibody for 30 min, and washed. Slides were then incubated with a labeling complex (streptavidin conjugated to horseradish peroxidase). A chromogen-substrate solution containing H.0, and diaminobenzidine (DAB) (Sigma Chemical Co.. St. Louis, MO) was incubated on each section. The slides were rinsed in running tap water, counterstained with a modified Harris hematoxylin (Harleco, Gibbstown, NJ), dehydrated, and coverslipped. Three sections of normal intestine were immunostained at the same time as positive controls. For a negative control, a nonleukemic spleen was incubated with preimmune mouse serum instead of the primary antibody to PCNA.
Staging Scheme. The staging system used was first described in the National Toxicology Program Technical Report Series (14) and later by Dunnick et al (2) . In Stage 1, the spleen is not enlarged or only slightly enlarged and contains small numbers of neoplastic LGLs in the red pulp. There are no or very few leukemic LGLs in the liver sinusoids, and no identifiable neoplastic LGLs are present in the vasculature of other organs. In Stage 2, the spleen is moderately enlarged with moderate to large numbers of neoplastic LGLs in the red pulp. The architectural features including the lymphoid sheaths [periarteriolar lymphoid sheaths (PALS)] remain intact. There is minimal to moderate involvement of the liver. Leukemic LGLs may be evident in blood vessels of other organs, but aggregates/masses of neoplastic LGLs generally are limited to the spleen and liver. Stage 3 LGL leukemia is marked by evidence of advanced disease. The spleen is markedly enlarged with effacement of normal architectural features by the accumulation of neoplastic LGLs. The liver is moderately to markedly enlarged and nodular. The hepatic parenchyma has variable degenerative and regenerative changes associated with the accumulation of neoplastic LGLs. Accumulation of neoplastic LGLs in other organs including lungs, lymph nodes, kidney, brain, and adrenal gland is usually present.
The staging scheme used by the National Toxicology Program was developed to provide consistency among pathologists in diagnosing early stages of the disease. It was found that there was considerable differences among pathologists in diagnosing the disease that made it difficult to tabulate and utilize an historical database (S. L. Eustis, National Institute of Environmental Health Sciences, personal communication). The staging system was not devised to define the progression of the disease.
Scoring. Duplicate (two) photomicrographs were taken of each section of spleen at a x 300 magnification, and approximately 1,000 cells in the center of each photograph were counted. All cells with positive nuclear staining (deep red brown coloration from the DAB precipitate; see Fig. 1 ) were identified and counted. Areas photographed were the most evenly and heavily labeled and were generally near the center of the histologic section.
In the nonleukemic spleen (Stage 0), photomicrographs were taken of both red pulp and marginal zones (morphologically the site of origin of LGL leukemia; see Fig. 1 ). LIs were calculated for both areas, as there was no detectable difference in either the LIs or MIs between the red pulp and marginal zones. In all leukemic spleens, photomicrographs were taken of neoplastic areas. Areas within the photomicrographs that were excluded from counting were foci of extramedullary hematopoiesis (EMH), trabeculae, and PALS or the white pulp. These areas were excluded because LGL leukemic cells are not reported to locate in these areas in appreciable numbers; thus, the affects from LGL leukemia are indirect (such as by compression). Furthermore, there is frequently an increase in splenic EMH associated with the anemia observed in the leukemic rats that would falsely increase the LI and MI. Conversely, trabeculae are not present in all areas counted and are less cellular than the red pulp or marginal zone; by counting the cells in trabeculae. the LIs and MIs could be falsely de- creased.
The number of PCNA labeled cells were divided by the total cells counted to obtain a percentage of labeled cells, or LI. Mitotic figures were also counted in the same area of the photograph and divided by the total numbers of cells counted, and a percentage, or MI, was calculated. Statistical analysis was performed for pairwise comparison of the LI and MI by Dunnett's procedure (1). Dunnett's procedure was chosen because of its nature to identify treatment differences between leukemic and control rats, but not to compare them. This procedure is also more conservative than the Student's t-test and is a desirable statistical test because of the small sample sizes. A standard linear regression ( 16) procedure was used to identify any trend present in the LI and MI of nonleukemic and the 3 stages of leukemia.
RESULTS
LI and MI means for all groups are listed in Fig.   2 , and the individual values are shown in the scatter plots in Figs. 3 and 4 . The line graph of the mean values in Fig. 2 shows an increased mean LI in Stages 2 and 3 when compared to the nonleukemic group (Stage 0). However, this increase was not sig- nificant, as determined by Dunnett's procedure. The scatter plot in Fig. 3 demonstrates the wide variability of values obtained, particularly in the Stage 3 group. A statistically significant increasing trend in advancing stages of leukemia is apparent in the PCNA LI in the scatter plot of Fig. 3 , as determined by linear regression (p = 0.0195).
The MI results differs from the LI results in that the means of all the LGL leukemia groups are significantly greater than the nonleukemic group when analyzed by Dunnett's procedure (p < 0.05). Although there is marked variability in the MI in leukemia stages (see the graph in Fig. 2 and the scatter plot in Fig. 4 ), the variability is less than that observed in the PCNA LI leukemic stages. No increasing trend of the MI in the LGL leukemia stages was detected by linear regression.
DISCUSSION
The F-344/N rat is used in toxicity and carcinogenicity studies because of the strain's inbred genetic characteristics. ease of maintenance, and sensitivity to various types of carcinogens. A comprehensive characterization of LGL leukemia is nec- FIG. 4. -Scatter plot of the MI. Line is calculated by linear regression. MI between stages is significant by Dunnett's procedure. Linear regression to test for trend by stage is not statistically significant. essary for an adequate assessment of potential treatment-related carcinogenicity. The proliferation rate of the neoplastic cells is but one of the parameters needing to be characterized. Furthermore, detecting differences in the proliferation rate between the described stages adds significance to the use of the current grading scheme in evaluating LGL leukemia in toxicity and carcinogenicity studies by other than morphologic terms.
The increasing PCNA LI trend and the increase in the MI in this experiment indicate that cells in LGL leukemic spleens from F-344/N rats proliferated at significantly higher rate than in the nonleukemic spleens. The lack of significance of Dunnett's pairwise comparison of the LI of leukemic groups to the nonleukemic group, even though there was a significant increased trend, is most likely due to the large variability in the leukemic stages, particularly the Stage 3 spleens, plus the small group size. However, the significant increase in the MI further supports the conclusion that LGL leukemia cells proliferate at a rate greater than do the normal LGLs.
Lymphoid neoplasms in humans have a much higher LI than the LGL leukemia in F-344/N rats with a mean LI of 26% for low-grade lymphomas or 54% for intermediate lymphomas versus a mean of 8.4% in LGL leukemia ofF-344/N rats (11) . Thus, even though neoplastic LGL proliferation is increased over that of LGLs in normal spleens. the proliferation rate is substantially less than that of neoplastic lymphocyte in human lymphoid tissues.
A cell population can expand by 2 methods, by either shortening the cell proliferation cycle or by decreasing the rate of cell loss, that is, cell death or apoptosis. The results of this study indicate that LGL leukemia in the F-344 rat has a proliferative component. However, because LGL leukemia in the F-344/N rat is considered an acute disease, the rate of proliferation determined may not be sufficient to expand the neoplastic LGL population at such a rapid rate. A lower rate of cell death may also contribute to the accumulation of neoplastic LGLs. The rate of cell death of the neoplastic relative to the normal LGLs is still not known. Assays to determine the life span of the leukemic cells compared to nonleukemic LGLs may answer this question.
